pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

976 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT824Endpoints620BioPharma Dive237onclive165Fierce Biotech90BioSpace87raps32globenewswire health26
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
    A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.
    BioPharma Dive · 2mo ago↗ source
  • Post-Hoc: Why FDA Commissioner Marty Makary was ousted
    Marty Makary never stood a chance. Over the last few days, the now-former FDA commissioner had been left to twist in the wind, after headlines emerged late last week that President Donald Trump had…
    Endpoints · 2mo ago↗ source
  • Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
    Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
← prev
page 31 of 40
next →
fda medwatch21
fda press21
fda recalls16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 2mo ago
↗ source
  • Behind Galapagos’ transformation into Lakefront Biotherapeutics
    CHICAGO — From a 22nd-floor office overlooking the Chicago Riverwalk, in the heart of the Midwest hub’s white-collar downtown district, Lakefront Biotherapeutics’ executives hope to stage the compa…
    Endpoints · 2mo ago↗ source
  • #ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapy
    BOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex ce…
    Endpoints · 2mo ago↗ source
  • [Podcast] Closing the Distance in Cancer Care
    This podcast episode explores the critical role community oncology plays in the U.S. healthcare system and why supporting its growth and autonomy matters for patients and providers.
    BioPharma Dive · 2mo ago↗ source
  • Merck KGaA's clients are stockpiling due to Iran war, supporting guidance boost
    Merck KGaA appears to have a big-picture view of how the Iran war is affecting the pharma industry so far. The German company is seeing an uptick in demand for its lab equipment products as ...
    Endpoints · 2mo ago↗ source
  • Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
    Reducing the dose of Eli Lilly’s obesity shot Zepbound could provide a safe, effective and potentially cheaper option for the maintenance of weight loss, according to new data. The findings come fr…
    Endpoints · 2mo ago↗ source
  • FDA chief Marty Makary resigns from agency, ending tumultuous tenure
    Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.
    BioPharma Dive · 2mo ago↗ source
  • EU reaches provisional deal on Critical Medicines Act
    The Critical Medicines Act reached its next milestone on Tuesday, after the European Parliament and the Council provisionally voted it through. The proposed regulation aims to improve the European…
    Endpoints · 2mo ago↗ source
  • FDA Commissioner Makary resigns
    FDA Commissioner Marty Makary has resigned after his job status hung in the balance for days. President Donald Trump confirmed the news Tuesday in a social media post. Makary’s decision centered ...
    Endpoints · 2mo ago↗ source
  • Iran war disruptions begin to emerge upstream of the pharma supply chain
    As the Iran war enters its third month, its knock-on effects on raw materials, energy costs and shipping are beginning to be felt in the pharma industry. While the Middle East is barely a player ...
    Endpoints · 2mo ago↗ source
  • What I learned at a journalism fellowship about covering healthcare AI
    Last week, I was reminded that reporting on AI in healthcare requires continuous scrutiny of the incentives that drive it. Thanks to a fellowship hosted by SABEW, in partnership with ...
    Endpoints · 2mo ago↗ source
  • Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
    A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
    BioPharma Dive · 2mo ago↗ source
  • Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
    Isomorphic Labs said Tuesday it had closed a $2.1 billion Series B round, cementing its bellwether role in using AI for drug discovery. For privately held companies, Isomorphic’s raise is the secon…
    Endpoints · 2mo ago↗ source
  • Pfizer and Arvinas give disappointing breast cancer drug to Rigel
    Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. T…
    Endpoints · 2mo ago↗ source
  • Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
    Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-qu…
    Endpoints · 2mo ago↗ source
  • Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
    Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…
    Endpoints · 2mo ago↗ source
  • Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AI
    A startup that spun out of UC Berkeley aims to improve healthcare operations by getting AI to think like a doctor would. Knit Health launched with $11.6 million in seed funding co-led by Uncork Cap…
    Endpoints · 2mo ago↗ source
  • Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
    The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.
    BioPharma Dive · 2mo ago↗ source
  • A year after Vertex’s big launch, pain drug research faces a pivotal moment
    Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
    BioPharma Dive · 2mo ago↗ source
  • Flagship startup Serif says it has solved non-viral gene therapy in monkeys
    BOSTON — Serif Biomedicines, a startup launched last month by Flagship Pioneering, believes it has solved two technical challenges that have long prevented gene therapy from being delivered without…
    Endpoints · 2mo ago↗ source
  • Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
    It's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it. China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Bris…
    Endpoints · 2mo ago↗ source
  • Optum Rx unveils pharmacy model with clear fees, building on transparency push
    UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said offers its customers transparency into the entire drug supply chain. Under the new model,…
    Endpoints · 2mo ago↗ source
  • Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
    It seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it wou…
    Endpoints · 2mo ago↗ source